Myths, mystique, and misconceptions of venous disease  by Comerota, Anthony J.
disease represent a preciously small percentage of clinical
practitioners. Observing current practice, even at major
medical centers, it is evident that nearly all facets of venous
disease are misunderstood by many, and most persons do
not have a grasp of venous disease in its entirety, as it
relates to both acute and chronic problems.
VENOUS DISEASE IS INCREDIBLY DIFFICULT
AND COMPLEX
The first misconception is that “venous disease is
incredibly difficult and complex.” This quote was recently
articulated at a national meeting by a recognized author-
ity in vascular disease and an expert in venous disease.
Such statements made by recognized experts disenfran-
chise the less well informed and erase enthusiasm for pur-
suing an understanding of venous disorders. I believe that
reference was being made to patients with chronic venous
insufficiency, although many physicians believe that acute
venous thrombotic disorders are also complex. It is my
opinion that venous disease is simple, in both the acute
and chronic forms. For acute venous thrombosis, we need
to understand the etiology of deep venous thrombosis
(DVT) to offer effective prophylaxis and understand the
natural history to integrate current treatment options to
reduce post-thrombotic consequences. In patients with
chronic venous insufficiency, we need to merely under-
stand the underlying pathophysiology so that appropriate
management can be offered.
I will begin with a quick look at chronic venous insuf-
ficiency and the post-thrombotic syndrome. The patho-
physiology has been elucidated by previous investigators,
and exercise-induced venous hypertension appears to be
the common denominator in the majority of patients.1,2
Only two problems occur in the venous system that con-
tribute to exercise-induced or ambulatory venous hyperten-
sion, and they are valvular incompetence and venous
obstruction. Once the underlying pathophysiologic param-
eters are identified, we can either begin a therapeutic strat-
egy to correct the abnormal physiology or accept it and
manage the symptomatic outcome, ie, the chronic
venous insufficiency syndrome. Technology offers us the
Serving as President of the American Venous Forum
has been a privilege and a great honor. All who have been
and will be elected president deliberate long and hard
about the address they will give, hoping to find inspira-
tion, with the desire that the observations, insight, and
information presented will last beyond the time allotted in
the program. I hope that the title of this address and the
issues discussed will stimulate some and challenge others
to extend their efforts to learn, educate, and investigate
venous disease.
Defining the terms we use in daily communication is
important for clarity of expression and understanding.
Misunderstanding frequently occurs when a word used is
defined differently by the persons involved. According to
Merriam-Webster’s Collegiate Dictionary (10th edition), a
myth is “… a person or thing having only an imaginary
existence.” Mystique is “… an air or attitude of mystery
and reverence developing around something or some-
one.” And misconception is “… bad or wrong, opposite
or lack of … (concept).”
For many years venous disease has been relegated as
the “stepchild” of vascular surgery. Patients with chronic
venous insufficiency were referred to the “clinic” to be
cared for by medical students and residents who were
often overseen by an uninterested attending staff.
Fortunately, perception and attitudes are changing.
The American Venous Forum has stimulated and
rewarded intellectual contributions, at both the clinical
and basic science level, thereby advancing the field.
However, organizations with a special interest in venous
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opportunity to clearly evaluate venous valve function, in
both the superficial and deep veins, from the inguinal lig-
ament to the ankle. Unfortunately, our ability to diagnose
and quantify obstruction is severely limited.
VENOUS OBSTRUCTION CAN BE DIAGNOSED
AND QUANTIFIED
Another myth of venous disease is that deep venous
obstruction can be adequately diagnosed or quantified. As
I reflect upon discussions and deliberations with col-
leagues, it is apparent that venous “obstruction” as a con-
cept is part of the mystique and misconception of chronic
venous disease. Obstruction is often conceptually defined
as occlusion! In reality, obstruction should be viewed in a
linear sense (as a spectrum) rather than “all or none” (Fig
1). If the vein lumen is not compromised, it is normal,
whereas obliteration of the lumen is occlusion. Everything
between 1% and 99% luminal compromise is “obstruc-
tion.” Important questions that are not yet answered
include the following:
1. At which point does obstruction impact venous return?
2. At which point can obstruction be detected?
3. What method/technique will be accepted as definitive?
An example of the misconception of obstruction is
illustrated by the patient with the post-thrombotic syn-
drome who underwent an ascending phlebogram which
was read as: “… the classic tree-barking appearance of
chronic venous disease, but there is no evidence of
obstruction” (Fig 2). A standard 3-second maximal
venous outflow test with an impedance plethysmograph
was obtained, and the value fell within the normal range;
therefore, all involved in the care of this patient agreed
that “obstruction” was not part of his problem.
A classic Linton procedure was performed, and the
femoral vein in the thigh was ligated and divided just
below the profunda. After examining the cross-sectional
image, it was apparent that although recanalization had
occurred, considerable luminal obstruction existed, which
did not become physiologically important until the patient
exercised.
The fundamental misconception is that obstruction
must be anatomically obvious and luminal obliteration
complete. Although venous obstruction is often anatom-
ically apparent, it should be defined physiologically.
Standard maximal venous outflow studies are poor indi-
cators of obstruction, especially for chronic disease. The
underlying pathophysiology in these patients occurs
when they are upright and exercising. However, we mea-
sure maximal venous outflow in the resting patient in the
supine and leg-elevated position. This is fundamentally
inconsistent. It appears that we are promoting this mis-
conception by accepting phlebogram interpretations of
scarred and recanalized veins as showing no obstruction
and by accepting maximal venous outflow results as
definitive.
Raju and Fredericks5 have thoughtfully sought to eval-
uate venous obstruction in the lower extremity on a phys-
iologic basis by using the arm-foot venous pressure
differential at rest and after postocclusive reactive hyper-
emia. This is an important contribution in the evaluation
of the role of venous obstruction in our patients.
Unfortunately, most of us do not incorporate these mea-
surements in our practice because they are cumbersome
and time-consuming, require physicians to perform the
procedures, and, of course, are uncomfortable for the
patient. The challenge is to develop a physiologic method
to evaluate obstruction that is noninvasive and patient
friendly and can be performed by vascular laboratory per-
sonnel. There is little doubt that thoughtful members of
this society or others in our profession can successfully
accomplish this goal, or at least make major strides in this
direction.
The myths and misconceptions of acute venous disease
are perhaps more subtle, but prevalent nonetheless. Our
ability to diagnose venous thromboembolic disease has
never been better, yet the choice and method of treat-
ment, duration of treatment, and even whether some
patients should be treated at all are continually argued by
physicians. The etiology of acute DVT is mystique for
some, whereas others have a poor or nonexistent under-
standing of the genesis of venous thrombosis.
VALVE CUSP HYPOXEMIA LEADS TO
ENDOTHELIAL DAMAGE AND DVT
It has been well established that the majority of “spon-
taneous” venous thrombi begin within the valve cusp.6
Localized hypoxemia of venous endothelium within the
valve cusp has been proposed and accepted by some
researchers as an important etiologic factor. Hamer et al7
reported their findings after measuring pO2 endoluminally
and in the valve pockets of veins in two patients and eight
dogs. Under conditions of constant flow, the blood within
the valve pockets rapidly became hypoxic, whereas the pO2
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Fig 1. Obstruction of the vein lumen, which contributes to
chronic venous insufficiency, should be viewed conceptually as
any compromise of the vein lumen between 1% and 99%.
Complete obliteration of the vein lumen is occlusion.
within the valve cusp in veins with pulsatile flow was similar
to that of luminal blood. The two patients studied in this
experiment were undergoing excision of varicose saphenous
veins, and the valve cusp studied was within 5 to 10 cm of
the saphenofemoral junction. In several animal specimens,
endothelial injury and valve cusp thrombus were observed.
Although the microelectrodes probed the valve cusp to
become properly positioned, thereby potentially causing
direct endothelial injury, the authors suggested that the
endothelium covering the valve cusps is dependent on lumi-
nal blood flow for its oxygen supply, and when they become
hypoxic, endothelial damage occurs, setting the stage for
thrombosis. Hamer and colleagues did not address the obvi-
ous clinical question, why isn’t DVT associated with clinical
conditions of profound hypoxemia? Professor Hamer was a
visiting professor in the Thrombosis Research Center at
Temple University in the mid 1980s, during which time sim-
ilar experiments were performed. Unfortunately, the results
could not be duplicated.
There is an alternative theory explaining why venous
thrombosis originates in the valve cusp, which has basic
experimental validation and direct human clinical correla-
tion. The theory is that venous endothelial damage occurs
as a result of venodilatation. The experiments performed
to test this theory involved animals and patients undergo-
ing surgical procedures. The endothelial damage occurs in
valve cusps, which are usually in an area of the vein wall
that is attenuated and thus susceptible to damage.
Anatomic studies have demonstrated marked thinning of
the vein wall in the area of side branches, which are adja-
cent to valve cusps.8
Dr Gwendolyn Stewart, with whom I had the privilege
of collaborating early in my career, developed the hypoth-
esis that venous endothelial damage occurred in veins dis-
tant from the site of operation, and that this damage was
related to operative venodilation resulting from the trauma
of the procedure.9,10 This work originally investigated the
canine model of total hip replacement and major abdomi-
nal operations. Animals undergoing operation and nonop-
erative controls were perfusion-fixed with formaldehyde,
and their jugular veins and femoral veins were harvested
(Figs 3 and 4). Animals on which surgery was performed
had substantially greater endothelial damage compared
with the controls, and this damage uniformly occurred
within the valve cusp.
A specially designed ultrasound probe was constructed
to continuously monitor venous diameter during the
operative procedure. Animals that had significant venodi-
lation during the operation had significantly greater
endothelial damage than those that had minimal or no
operative venodilation.11
We extended this experiment to human patients under-
going total hip reconstruction,12 and subsequently total
knee reconstruction,13 using postoperative phlebograms
(DVT) as the endpoint. The cephalic vein opposite the hip
on which surgery was performed was continuously moni-
tored, and venous diameter was recorded during the oper-
ation. Patients were randomized to receive the venotonic
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agent dihydroergotamine heparin or placebo preopera-
tively and postoperatively. All patients had postoperative
ascending phlebography. The results showed significant
correlation of operative venodilatation with postoperative
DVT. Patients who developed DVT had a mean operative
venodilatation of 29% compared with only 11% for patients
who did not develop postoperative DVT (P = .0012).12
Interestingly, there appeared to be two groups of patients,
those who had pronounced operative venodilation and
those who had minimal venodilatation. In the group dilat-
ing less than 20% of their baseline diameter, postoperative
DVT developed in only 17% of patients. In patients who
dilated more than 20% of their baseline diameter, phlebo-
graphically proven DVT developed in 100%. Interestingly,
older patients had greater operative venodilation and a
higher incidence of postoperative DVT.
Patients who underwent total knee replacement had
minimal operative venodilatation (with the exception of
one outlier), yet had a very high incidence of postoperative
DVT (82%). At first glance this might seem to contradict
the theory of humorally mediated venodilatation resulting
in venous endothelial damage. However, understanding
that a thigh tourniquet is applied to the affected leg before
skin incision and released after the operation is complete,
one realizes that there is no direct circulating correction of
the wound with the patient’s body. Therefore, if venodi-
latation is humorally mediated, patients undergoing total
knee reconstruction should not have operative venodilata-
tion in distant veins because the products of tissue injury
do not escape the leg during the procedure. This was the
experimental observation. The expected clinical correlation
followed, that ipsilateral DVT after total knee replacement
is common but contralateral DVT is unusual.
The hypothesis is that vasoactive mediators, which are
products of tissue injury, are produced at the wound, enter
Fig 2. A, Cross-section photograph of the proximal femoral vein
of a post-thrombotic man with venous ulceration who had a clas-
sic Linton procedure performed. The femoral vein below the pro-
funda femoris vein was ligated and divided. Note multiple-channel
recanalization of vein lumen; however, a large percentage of the
vein lumen is “obstructed.” B, An ascending phlebogram of the
patient’s leg preoperatively shows the recanalized femoral vein;
however, the official interpretation indicated that there was
“chronic disease but no evidence of obstruction.”
A B
the blood stream, and survive long enough to have an
effect on venous smooth muscle in veins distant from the
site of the operation. This vasodilatory response results in
endothelial damage, most frequently in the area of the
valve cusp, because of attenuation of the wall in this area.
This fits with the observations of Sevitt and Gallagher,6
that thrombus originates within the valve cusp. I believe
that this theory also explains the results of the radioactive
fibrinogen uptake tests (RFUTs) that had been used to
evaluate DVT in postoperative patients. The RFUT has
been associated with a large number of false positives
when compared with postoperative phlebography, espe-
cially in calf veins. It is likely that the radioactive fibrino-
gen is bound to the areas of endothelial injury in the valve
cusp; however, many of the injured sites did not result in
phlebographically visible thrombosis, explaining the dis-
crepancy between these studies. Because valves are more
prevalent in the calf veins than in the proximal veins, the
chance of this observation occurring in calf veins is
increased.
THE SUPERFICIAL FEMORAL VEIN IS
SUPERFICIAL
When venous thrombosis is located in the lower
extremity between the popliteal and common femoral
veins, we say that the “superficial femoral vein” is
involved. Although those of us in the vascular specialties
recognize that the superficial femoral vein is the major
deep vein in the thigh, we are promoting the misconcep-
tion that the patient has “superficial venous thrombosis”
by using this term. This misconception is dangerous
because of the potential ramifications of nontreatment of
proximal DVT.
Our former president, Dr John Bergan, spearheaded
an important study that culminated in the paper “The
superficial femoral vein: A potentially lethal misnomer”.14
He and his associates surveyed family physicians and
internists, chairpersons of the departments of anatomy, and
directors of noninvasive vascular laboratories. They found
that only 24% of clinicians would treat patients for DVT if
they knew their patient had blood clots in the superficial
femoral vein. Only 3% of the anatomists thought the term
“superficial femoral vein” was correct, although 22%
thought it was acceptable. Only 9% taught this term to
medical students. Therefore, although 91% of anatomy
courses teach otherwise, 93% of the vascular laboratories
use the term “superficial femoral vein” when reporting
results of lower-limb venous duplex examinations.
It appears that it was not until 1941 that the term
“superficial femoral vein” referred to the vein correspond-
ing to the superficial femoral artery in the thigh.
Homans15 described ligation and division of deep veins to
prevent pulmonary emboli in patients with DVT. Since
then, these terms have become accepted and used with
increasing frequency by vascular surgeons, vascular inter-
ventionalists, and vascular laboratories.
Referring to the standard textbook, Gray’s Anatomy,16
one cannot find the term superficial femoral vein. The
book states, “The femoral vein is that which accompanies
the femoral artery through the proximal 2⁄3 of the thigh. It
receives numerous muscular tributaries and about 4 cm
below the inguinal ligament is joined by the V. profunda
femoris; near its termination it is joined by the great
saphenous vein.”16
A frequently read and studied anatomy text is Clinical
Anatomy by Ellis.17 It refers to the veins of the lower
extremity as “…deep and superficial groups according to
their relationship to the investing deep fascia of the leg.
The deep veins accompany the corresponding major arter-
ies. The superficial veins are the long and short saphenous
veins and their tributaries.” 17
Therefore, it appears that we have no one to blame but
ourselves for propagating the misconception that what we
refer to as the “superficial femoral vein” is truly superficial.
I propose that we abandon this term, and for those of us
who are involved with vascular laboratories, that we remove
it from our reporting nomenclature. I am certain that this
will improve patient care by transmitting accurate informa-
tion to the referring physician, and patients with DVT
extending into the thigh will be appropriately managed.
CALF-VEIN THROMBOSIS IS CLINICALLY
UNIMPORTANT
A common misconception is that isolated calf-vein
thrombosis is inconsequential. Natural history studies
have demonstrated that patients with isolated calf-vein
thrombosis have a higher frequency of post-thrombotic
symptoms.18 Many of us are aware of the occasional high-
profile patient who has isolated calf-vein thrombosis and
receives instruction to return in 3 to 4 days for a repeat
venous duplex evaluation. Before returning, the patient
collapses as a result of a massive or, occasionally, fatal, pul-
monary embolism. While none of us would presume that
the calf clot was responsible for the pulmonary embolism
and certainly not for a fatal pulmonary embolism, calf
DVT was unquestionably a marker for more extensive
thrombosis elsewhere, most likely in the proximal nonax-
ial veins. Some of the issues contributing to the miscon-
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Fig 3. Scanning electron micrograph of the jugular vein of a dog
that had 6 hours of general anesthesia but no operation. Jugular
vein dilated minimally (<10% of baseline diameter) during the
experiment. A, High-power magnification showing a smooth,
intact endothelial monolayer. B, Lower-power magnification
showing normal endothelium and a normal valve cusp (–N).
A B
ceptions of the importance of calf DVT are their variable
natural history, whether patients are symptomatic or
asymptomatic, and whether the calf-vein thrombi are
found incidentally on screening examinations of patients
who are no longer at high risk or symptomatic outpatients
who may be in early stages of their thrombotic event.
Several studies reviewing isolated calf-vein thrombosis
conclude that propagation occurs in 6% to 30% of postop-
erative and hospitalized patients, and early propagation
occurs in 10% of symptomatic patients.19,20 A prospective
trial randomized patients with isolated calf DVT to either
5 days of intravenous heparin followed by no additional
therapy or 3 months of anticoagulation.21 Patients who
were anticoagulated had no recurrent venous throm-
boembolic events, compared with a 29% recurrence in the
no-treatment group. Meissner et al18 followed 29 patients
with isolated calf DVT as part of a natural history study.
Seventy percent were symptomatic at diagnosis. Patients
were followed clinically and with venous duplex for at least
1 year. Recanalization occurred rapidly, with the mean
thrombus load reduced by 50% at 1 month. Twenty-three
percent had post-thrombotic symptoms at 1 year. Venous
valvular incompetence was progressive during follow-up,
with reflex present in 24% of patients at 1 year. It is appar-
ent that many patients with calf DVT will benefit from a
shortened course of anticoagulation. I suggest a treatment
strategy that incorporates the patient’s ongoing risk fac-
tors and potential comorbidities for bleeding. If the etiol-
ogy for the patient’s calf DVT is identified and corrected,
the patient should be at low risk for propagation and
recurrence and can be followed with duplex. However, if
the patient continues to be at risk or if the etiology is not
defined, I would suggest a shortened course of anticoagu-
lation for 3 months.
ANTICOAGULATION IS BEST MANAGED BY
PHYSICIANS
Anticoagulation is the recommended treatment for the
majority of patients with venous thromboembolism. The
adverse events of poor anticoagulation control are the con-
sequences of excessive anticoagulation (hemorrhage) or
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subtherapeutic anticoagulation (thrombosis). Numerous
studies have shown a strong relationship between time in
therapeutic range and bleeding or thromboembolic rates.
Therefore, time in therapeutic range can be used as a mea-
sure of overall effectiveness of the method of oral antico-
agulation.
There is a widely held misconception that the physi-
cian most effectively manages the patient’s anticoagula-
tion. Although the majority of patients have their
anticoagulation controlled by their personal physician,
most physicians do not have an organized program of
management, education, or follow-up. Several studies
have shown that physician-controlled anticoagulation
results in only 33% to 59% time in therapeutic range.22-25
If responsibility shifts from the physician to an antico-
agulation clinic, there appears to be improvement in anti-
coagulation with time in therapeutic range increasing to
59% to 86%.26-29 Reducing subtherapeutic and excessive
anticoagulation avoids thrombotic and hemorrhagic com-
plications, resulting in a cost savings of $860 to $1,320
per patient-year of therapy.30
With advancements in technology, point-of-care test-
ing has developed and is a highly accurate and reliable
technique.31-33 Several small, portable instruments have
been developed through which a patient can obtain his
own prothrombin time from a simple finger stick. Patient
self-testing has been studied, with the patient calling the
blood-test result in to his physician’s office for dosage adjust-
ment, resulting in a further improvement (to 93%) in the per-
centage of time the patient is in the therapeutic range.34
Patients can be educated to use the point-of-care test
results to manage their own dosage adjustments. Several
studies have demonstrated that patient self-management
also results in an improvement in the time in therapeutic
range, 57% to 92%, which is generally better than man-
agement by a physician or an anticoagulation clinic.22,25,28
Taking anticoagulation management to the final level
is the removal of all human judgement by virtue of a com-
puter program. A computerized dosing regimen showed
equivalent performance compared with an experienced
medical staff in achieving a target international normalized
Fig 4. Scanning electron micrograph of the jugular vein of a dog that had a total hip replacement (OP).
The jugular vein dilated >28% of baseline diameter during the experiment. A, Low-power magnification
showing vein lumen and valve leaflet; note damage to vein wall in valve cusp. B, High-power magnifica-
tion showing all of the elements of thrombus on the injured surface. C, Intermediate magnification shows
tearing injury of endothelium within the valve cusp.
A B C
ratio of 2.0 to 3.035; however, the computer demonstrated
significantly better control when more intensive therapy
was required (international normalized ratio, 3.0-4.5).
Ageno and Turpie36 studied patients with prosthetic car-
diac valves who required anticoagulation with a comput-
erized warfarin adjustment program. Results were similar
to those achieved by manual regulation in terms of the
percentage of patients maintained within the therapeutic
range; however, the computerized program required 50%
fewer dosage adjustments. Poller at el37 reported results of
a multicenter randomized study of computerized antico-
agulant dosage and showed a 22% overall improvement of
control with the computerized program compared with
management by the medical staff.
THE PROPHYLACTIC BENEFIT OF 
INTERMITTENT PNEUMATIC COMPRESSION
IS LIMITED TO MECHANICAL ACCELERATION
OF VENOUS RETURN
Intermittent pneumatic compression (IPC) is an effec-
tive mechanical method of DVT prophylaxis. Although a
number of investigators have shown IPC to have favorable
hematologic effects in reducing blood coagulability, pre-
dominately by increasing endogenous fibrinolytic activ-
ity,38-40 many still believe that the benefit of IPC is limited
to mechanical acceleration of venous return. Among
researchers who recognize that IPC stimulates endoge-
nous lytic activity, a second misconception is that the
increased fibrinolytic activity is caused by endothelial
release of tissue plasminogen activator. There are likely to
be several reasons for these misconceptions. First, in stud-
ies denying the lytic effects of IPC, fibrinolytic activity was
not routinely measured.41 Components of the fibrinolytic
system were used as surrogate endpoints, namely tissue
plasminogen activator (t-PA) antigen and t-PA activity, as
well as the rapid-acting inhibitor plasminogen activator
inhibitor-1 (PAI-1). Because fibrinolytic activity is the
result of activation of plasminogen to plasmin by both t-
PA and urokinase type plasminogen activator (u-PA), and
because assays for u-PA are not readily available, the true
fibrinolytic effect will be missed if overall fibrinolytic activ-
ity is not measured. Moreover, if u-PA increases with IPC,
there will be a down regulation of t-PA,42 leading one to
believe that there is no change in lytic effect because of
minimal changes in t-PA antigen.
t-PA activity is, in fact, increased with IPC,40 but not
as a result of stimulation of t-PA antigen. IPC-enhanced
plasma fibrinolytic activity is associated with a decrease in
plasma t-PA antigen, PAI-1 antigen, and PAI-1 activity, but
with an increase in t-PA activity caused by a marked
decrease in PAI. Patients with post-thrombotic venous dis-
ease have significantly lower baseline and stimulated fibri-
nolytic activity.40 If post-thrombotic patients are included
in study samples but not recognized and stratified, the true
fibrinolytic effects of IPC will be underestimated.
Another important but not well-recognized hemato-
logic effect of IPC is the stimulation of tissue factor path-
way inhibitor (TFPI). The initiating mechanism of blood
coagulation is the tissue factor–dependent pathway. Tissue
factor pathway is initiated when factor VIIa is exposed to
tissue factor, which leads to the tissue factor VIIa complex,
which activates factor X. Because TFPI is a major modula-
tor of the tissue factor pathway, mobilization of pools of
TFPI can be an important component of the antithrom-
botic effects of IPC. Chouhan et al43 demonstrated a sig-
nificant increase in TFPI and a decrease in plasma
factor VIIa with IPC, in both normal subjects and post-
thrombotic patients. There are likely to be additional
effects of IPC on the coagulation cascade that have yet
to be investigated.
THROMBOLYTIC THERAPY IS OF NO
BENEFIT FOR THE TREATMENT OF VENOUS
THROMBOEMBOLISM
Pulmonary embolism. Thrombolytic therapy for
venous thromboembolism is underused, in part, because of
the misconception that therapy is of no proven benefit in
patients with pulmonary embolism or venous thrombosis.
The early clinical trials sponsored by the National
Institutes of Health (NIH) evaluating thrombolytic ther-
apy versus standard anticoagulation for pulmonary
embolism demonstrated consistent arteriographic, lung-
scan, and hemodynamic improvement in patients treated
with urokinase and streptokinase.44,45 Lytic therapy
rapidly improved the arteriographic and lung-scan find-
ings during the resolution of pulmonary emboli (P < .05).
Thrombolytic therapy also reduced pulmonary artery and
right atrial pressure.
Although there was a 42% bleeding complication rate
with lytic therapy, this was mostly caused by the multiple
invasive procedures performed as part of the protocol. A
27% bleeding complication rate was observed in patients
receiving standard anticoagulation. Because there was no
difference in mortality between the two treatment groups,
it is often concluded that lytic therapy was of no benefit.
This is an inappropriate conclusion, because all patients
with pulmonary emboli were randomized, not just those
who were at risk of dying. Most patients with pulmonary
emboli who are treated with anticoagulation do not die.
Furthermore, these trials were not powered to show a
mortality benefit.
Physiologic studies subsequently performed on
patients in the NIH-sponsored trials evaluated the basic
functional unit of the lung by measuring pulmonary cap-
illary blood volume and oxygen-diffusing capacity.46 At 1-
year follow-up, significant benefit was found in patients
treated with lytic therapy; such patients demonstrated
greater pulmonary capillary blood volume and oxygen-
diffusing capacity.
A 7-year follow-up evaluation was also performed, in
which these patients were studied with right-sided heart
catheterization.47 Pulmonary artery pressures and pul-
monary vascular resistance were measured with the patient
at rest and exercising. Patients treated with lytic therapy
had significantly lower pulmonary artery pressures and
pulmonary vascular resistance both at rest and after exer-
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cise. In addition, when the patient’s functional status was
evaluated, 73% (8/11) of patients treated with heparin
were classified as New York Heart Association Functional
Class III-IV, compared with 25% (4/12) of patients who
were treated with a lytic agent.
Contemporary trials of thrombolytic therapy for pul-
monary embolism have used urokinase and the newer lytic
agent recombinant tissue plasminogen activator (rt-PA),
which is nonantigenic and causes minimal, if any, allergic
reaction. The newest agent to be studied is reteplase.48
Petitpretz et al49 treated 14 patients with acute life-
threatening pulmonary embolism with large-dose uroki-
nase delivered directly into the right atrium. Compared
with pretreatment observations, 12 of the 14 patients
showed a significant decrease in their pulmonary vascular
obstruction and a significant reduction in their total pul-
monary vascular resistance. There were no serious bleeding
complications, and, interestingly, the majority of hemody-
namic improvement occurred within the first 3 hours.
The Plasminogen Activator Italian Multicenter Study-
2 investigators randomized 36 patients to receive either rt-
PA as a 10-mg bolus followed by 90 mg infused over 2
hours or full anticoagulation with heparin.50
Arteriographic improvement was significant in the rt-PA
group but nonexistent in the group receiving heparin.
Pulmonary artery pressures were significantly reduced in
the lytic group and somewhat increased in heparin-treated
patients. There was no difference in bleeding complica-
tions. Goldhaber and colleagues51 addressed the impor-
tant question of whether thrombolytic therapy for
pulmonary embolism improved right-ventricular function
and pulmonary perfusion as compared with anticoagula-
tion alone. Significantly more rt-PA patients had improve-
ment in right-ventricular wall motion and pulmonary
perfusion. Interestingly, in the heparin-treated group, two
patients had subsequent fatal pulmonary emboli and three
had additional nonfatal pulmonary emboli. Recently, the
results of a multicenter registry for pulmonary emboli
were reported and should be helpful to all who hope to
place thrombolytic therapy for pulmonary embolism into
proper perspective. Konstantinides et al52 reported that
the overall 30-day mortality was significantly lower in the
169 patients who received thrombolytic agents than the
550 patients who received anticoagulation alone (4.7% vs
11.1%, P = .016). Primary thrombolysis was the only inde-
pendent predictor of survival that reached statistical sig-
nificance with multivariate analysis. The 30-day mortality
after primary thrombolysis was also lower than that after
anticoagulation by defining the patients on the basis of
presenting characteristics such as age (<65 years, 3.0% vs
9.2%; >65 years, 7.1% vs 12.6%), arterial hypotension
(4.1% vs 14.9%), arterial normotension (5.0% vs 8.1%), syn-
cope (4.1% vs 17.9%), no syncope (4.9% vs 8.9%), no recent
major surgery (2.9% vs 12.3%), and right-ventricular
enlargement on echocardiography (4.7% vs 11.1%).
Mortality was higher with thrombolysis than with heparin
in postoperative patients (12.5% vs 7.6%). The clinical fac-
tors that were associated with higher mortality for both
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groups were the presence or absence of syncope (14.4% vs
7.8%, P = .12), arterial hypotension (12.6% vs 3.7%, P =
.021), congestive heart failure (13.9% vs 7.7%, P = .13),
and chronic pulmonary disease (17.1% vs 8.8%, P = .032).
Among the other adverse events, major bleeding was
higher (21.9% vs 7.8%), whereas recurrent pulmonary
embolism was lower (7.7% vs 18.7%, P < .001) with
thrombolysis than heparin. Recurrent pulmonary emboli
were more common in patients with evidence of proximal
DVT (17.2% vs 11.4%, P = .06) and the echocardiographic
presence of right-sided thrombi (26.7% vs 15.9%, P = .09).
Two intracranial bleeds and one hemorrhagic death
occurred in each group.
Iliofemoral DVT. There is a broad-based misconcep-
tion that removal of clot from the deep venous system of
patients with iliofemoral DVT is of no value. It is also
interesting to note that vascular surgeons in the United
States do not hesitate to operate on patients with acute
iliofemoral arterial thrombosis, but if the same or a greater
volume of thrombus is located in the adjacent vein, there
is general reluctance to operate, despite prospective ran-
domized data demonstrating that thrombus removal from
the iliofemoral venous system with surgical thrombectomy
and arteriovenous fistula offers significantly better out-
come than does anticoagulation alone.53,54
Catheter-directed thrombolysis is a pharmacologic
approach designed to clear the thrombus from the
iliofemoral venous system that can be applied to the major-
ity of patients with iliofemoral venous thrombosis. We
know that the post-thrombotic morbidity of iliofemoral
DVT is severe55,56 and that eliminating thrombus and
restoring patency eliminates obstruction. Avoiding obstruc-
tion significantly reduces the virulence of the post-throm-
botic syndrome.3,4 In addition, it has been shown that early
clot resolution offers the potential of preserving valvular
function.57
During the past 13 years, 55 patients were treated with
catheter-directed thrombolysis for occlusive iliofemoral and
vena caval thrombosis at Temple University Hospital. The
technique has evolved from urokinase infusions via a con-
tralateral femoral and internal jugular-vein catheter placed
into the clot to rt-PA at a 2-mg to 6-mg bolus and a 2-mg/h
to 4-mg/h infusion, or the combination of an abciximab
0.25-mg/kg bolus + 0.125 µg/kg/min × 12 h + reteplase
at 0.5 U/h, via an ultrasound-guided popliteal-vein or pos-
terior tibial–vein catheter insertion. Forty-six of 55 patients
(84%) had a successful outcome. Complications included
puncture site hematoma in 8 patients (15%), blood transfu-
sions required in 4 patients (7%), operative evacuation of a
hematoma and repair of a common femoral vein required in
1 patient (2%), and 1 guidewire perforation of the common
femoral vein (2%). Twenty-six percent of the patients were
asymptomatic after therapy, and 52% had moderate
improvement. Twenty-two percent of the patients were
either unchanged or had only mild clinical improvement.
Mewissen et al58 reported the largest series of
catheter-directed thrombolysis for lower-extremity DVT.
Their findings from the National Venous Registry and the
findings of Bjarnason et al59 confirmed that 80% to 85% of
patients with iliofemoral DVT can have a successful out-
come when treated early in the course of their venous
thrombosis. The complication rate remains relatively con-
sistent and acceptable at 7% to 12%. Only one patient
among three large series developed an intracranial bleed,
and one patient died of a fatal pulmonary embolism dur-
ing therapy.
After patient recruitment to the Venous Registry was
completed, a study assessing health-related quality of life
was designed to evaluate whether catheter-directed throm-
bolysis for iliofemoral DVT was associated with improved
quality of life as compared with standard anticoagulation
and whether health-related quality of life outcome in the
thrombolysis group was related to lytic success.
An 80-item health-related quality of life questionnaire
was developed and validated.60 The validated question-
naire was then administered to 98 patients with iliofemoral
DVT treated at least 6 months earlier. Sixty-eight patients
who were treated with catheter-directed thrombolysis
were identified through the National Venous Registry, and
30 patients who were treated with anticoagulation alone
were identified through their physician or a medical-
record review.61
The lytic group was younger (mean, 53 years) than the
heparin group (mean, 61 years). After treatment, patients
receiving catheter-directed thrombolysis reported better over-
all physical functioning (P = .046), less stigma (P = .033), less
health distress (P = .22), and fewer post-thrombotic symptoms 
(P = .006) as compared with patients treated with antico-
agulation alone. Within the lytic group, phlebographic-
ally successful lysis correlated with an improved
health-related quality of life (P = .038). Interestingly, lytic
failures and heparin treatment outcomes were similar.
Failure of catheter-directed thrombolysis did not adversely
affect outcome as compared with standard anticoagulation
alone.
These data serve as an important foundation for the
design of a randomized trial evaluating the treatment of
patients with acute iliofemoral DVT. Such a trial should be
multicenter and incorporate a strategy of thrombus
removal versus anticoagulation alone. Preliminary discus-
sions with the NIH have been instituted. If the NIH
expresses the sentiment that such an effort would be
worthwhile, an application will be forthcoming with the
members of this organization forming the nucleus of the
clinical investigators.
SUMMARY
I have addressed a number of myths and misconcep-
tions of venous disease, but there are many left to be dis-
cussed. There are not many randomized trials available
from which to draw definitive conclusions. Many basic and
clinical investigations lack the scientific rigor to allow firm
conclusions; yet, the information can be enormously valu-
able. By objectively evaluating existing data and using avail-
able information integrated with known physiologic and
pathophysiologic mechanisms, myths and misconceptions
will disappear and understanding will be clarified. It is evi-
dent that “venous disease” encompasses many specialties,
at both the basic science and clinical levels, which may con-
tribute to the mystique of venous disease. Although the
disciplines involved may be diverse, the principles underly-
ing the management of venous disease remain simple.
I thank Ebony Mason and Richard Throm for their
excellent editorial assistance.
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